Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer

Journal of Gene Medicine

Volumn 2, Issue 2, 2000, Pages 97-106

  Xiang, J ^a   Gomez Navarro J ^a   Arafat, W ^a   Liu, B ^a   Barker, S D ^a   Alvarez, R D ^b   Siegal, G P ^b   Curiel, D T ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus; Apoptosis; Bax; Chemotherapy; Ovarian cancer; Taxol

Indexed keywords

ADENOVIRIDAE;

BAX PROTEIN, HUMAN; ONCOPROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL CULTURE; DRUG EFFECT; FEMALE; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY;

ADENOVIRIDAE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034153542     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S     Document Type: Article

References (65)

1. Heppner GH, Miller BE. Therapeutic implications of tumor heterogeneity. Semin Oncol 1989; 16: 91-105.
2. Kem DH. Heterogeneity of drug resistance in human breast and ovarian cancers. Cancer J Sci Am 1998; 4: 41-45.
3. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.
4. Staunton MJ, Gaffney EF. Apoptosis: basic concepts and potential significance in human cancer. Arch Pathol Lab Med 1998; 122: 310-319.
5. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11: 68-75.
6. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-542.
7. Kamesaki H. Mechanisms involved in chemotherapy-induced apoptosis and their implications in cancer chemotherapy. Int J Hematol 1998; 68: 29-43.
8. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
9. Favrot M, Coll JL, Louis N, Negoescu A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther 1998; 5: 728-739.
10. Leonard CJ, Canman CE, Kastan MB. The role of p53 in cell-cycle control and apoptosis: implications for cancer. Important Adv Oncol 1995; 33-42.
11. Cascinu S, Graziano F, Del Ferro E, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998; 83: 1917-1922.
12. Trepel M, Scheding S, Groscurth P, et al. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia 1997; 11: 1842-1849.
13. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998; 8: 17-23.
14. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
15. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
16. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996; 93: 14559-14563.
17. Narita M, Shimizu S, Ito T, et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA 1998; 95: 14681-14686.
18. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998; 281: 2027-2031.
19. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
20. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
21. Ito T, Fujieda S, Tsuzuki H, et al. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999; 140: 81-91.
22. Molica S, Dattilo A, Giulino C, Levato D, Levato L. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica 1998; 83: 1122-1124.
23. Ogura E, Senzaki H, Yamamoto D, et al. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol Rep 1999; 6: 365-369.
24. Sturm I, Kohne CH, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999; 17: 1364-1374.
25. Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999; 86: 913-920.
26. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 1998; 4: 1071-1074.
27. Yagi OK, Akiyama Y, Nomizu T, et al. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. Gostroenrerofogy 1998; 114: 268-274.
28. Brimmell M, Mendiola R, Mangion J, Packham G. BAX frame-shift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16: 1803-1812.
29. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997; 3: 1228-1232.
30. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270: 96-99.
31. Sakakura C, Sweeney EA, Shirahama T, et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 1996; 67: 101-105.
32. Sakakura C, Sweeney EA, Shirahama T, et al. Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide. Surg Today 1997; 27: 676-679.
33. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br J Cancer 1998; 77: 1562-1567.
34. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 1999; 59: 2121-2126.
35. Xiang J, Piche A, Rancourt C, Gómez-Navarro J, Siegal GP, Alvarez RD, et al. An inducible recombinant adenoviral vector encoding box selectively induces apoptosis in ovarian cancer cells. Tumor Targeting 1999; 4: 1-9.
36. Schmolling J, Reinsberg J, Wagner U, Krebs D. Anti-TAG-72 antibody B72.3 - immunological and clinical effects in ovarian carcinoma. Hybridoma 1997; 16: 53-58.
37. Anton M, Graham FL. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J Virol 1995; 69: 4600-4606.
38. Rosenfeld ME, Feng M, Michael SI, et al. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res 1995; 1: 1571-1580.
39. Xiang H, Kinoshita Y, Knudson CM, et al. Bax involvement in p53-mediated neuronal cell death. J Neurosci 1998; 18: 1363-1373.
40. Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997; 16: 358-363.
41. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 1998; 58: 4776-4781.
42. Gómez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999; 35: 867-885.
43. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187: 127-137.
44. Nielsen LL, Maneval DC. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52-63.
45. Piche A, Grim J, Rancourt C, et al. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998; 58: 2134-2140.
46. Deshane J, Loechel F, Conry RM, et al. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1994; 1: 332-337.
47. Dole MG, Clarke MF, Holman P, et al. Bcl-xS enhances adenoviral vector-induced apoptosis in neuroblastoma cells. Cancer Res 1996; 56: 5734-5740.
48. Ealovega MW, McGinnis PK, Sumantran VN, Clarke MF, Wicha MS. bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 1996; 56: 1965-1969.
49. Clarke MF, Apel IJ, Benedict MA, et al. A recombinant bcl-xs adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA 1995; 92: 11024-11028.
50. Pietersen AM, van der Eb MM, Rademaker HJ, et al. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther 1999; 6: 882-892.
51. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
52. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int J Oncol 1999; 15: 793-802.
53. Roth W, Isenmann S, Naumann U, et al. Locoregional Apo2L/ TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.
54. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
55. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165-1170.
56. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997; 277: 768
57. Noteborn MH, Zhang YH, van der Eb AJ. Apoptin specifically causes apoptosis in tumor cells and after UV-treatment in untransformed cells from cancer-prone individuals: a review. Mutat Res 1998; 400: 447-455.
58. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-741.
59. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 1996; 93: 14094-14099.
60. Coll JL, Negoescu A, Louis N, et al. Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis. Hum Gene Ther 1998; 9: 2063-2074.
61. Jaattela M. Heat shock proteins as cellular lifeguards. Ann Med 1999; 31: 261-271.
62. Khuu H, Conner M, Vanderkwaak TJ, Shultz J, Gómez-Navarro J, Alvarez RD, et al. Coxsackie-adenovirus receptor (CAR) is a universal marker for ovarian tumors of epithelial derivation. Appl Immunohistochem 1999; 7: 266-270.
63. Vanderkwaak TJ, Wang M, Gómez-Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999; 74: 227-234.
64. Strobel T, Swanson L, Korsmeyer S, Cannistra SA, BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 1996; 93: 14094-14099.
65. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992; 52: 4196-4199.